Intra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Lipoprotein(a) [Lp(a)] is a casual and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and is largely genetically determined. However, recent studies indicate significant intra-individual variability, particularly among patients with intermediate Lp(a) levels (30–50 mg/dL). Yet, data on long-term variability are limited, and acute coronary syndrome (ACS) may further influence Lp(a) levels, questioning the optimal timing of assessment after ACS. Methods: We studied 235 ACS patients across two follow-up cohorts. Baseline Lp(a) was measured 24 hours before hospital discharge. Cohort A had follow-up measurements at 4 months, and 8 months; Cohort B at 5 years. Clinically meaningful intra-individual variability was defined as ≥20 mg/dL or ≥25% change. Results: A total of 57.9% patients exhibited clinically significant Lp(a) variability. Changes in risk category occurred in 15.3% of patients in the baseline high-risk group, 60.6% of patients in the intermediate-risk group, and 5.5% of patients in the baseline low-risk group. At multivariable analysis incomplete revascularization was an independent predictor of high Lp(a) variability (OR 2.22; 95% CI 1.14-4.31; p 0.02) while female sex, and age-adjusted menopause showed a trend (OR 1.92; 95% CI 0.93-4.00; p 0.08 and OR 11.18; 95% CI 0.79-157.58; p 0.07, respectively) without reaching formal statistical significance. The median absolute changes from baseline to 4-month and from baseline to 5-years follow-up were 7.9 mg/dL (IQR 3.0-18.9) and 10.7 mg/dL (IQR 3.0-21.7), respectively. Concordance between 4- and 8-month Lp(a) measurements was excellent. Conclusions: Early post-ACS intra-individual variability in Lp(a) is common, mainly affecting risk reclassification in intermediate-risk patients. In those patients, early targeted repeat Lp(a) measurement may improve cardiovascular risk stratification, whereas mid- to long-term reassessment appears unnecessary.

Article activity feed